clinical trial · NCT06298565
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
argenx·—·recruiting·n = 680
Myasthenia Gravisefgartigimod
brief summary
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.
started
Nov 4, 2024
primary completion
Jun 1, 2034
completion
Jun 1, 2034
last updated
Feb 17, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol